New biosimilar AVT80 compared to entyvio in healthy adults
NCT ID NCT06732804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested a new biosimilar called AVT80 against the approved drug Entyvio in 385 healthy adults aged 18 to 55. The goal was to see how similarly the body processes each drug, and to check safety and immune reactions. Participants received a single injection of either AVT80 or one of two versions of Entyvio, and researchers compared drug levels and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AVT80 (a proposed biosimilar to Entyvio)
What this could lead to
If successful, this could support AVT80 as a more affordable alternative to Entyvio for treating inflammatory bowel disease.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only checks how the drug moves through the body and safety, not whether it works for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MALE AND FEMALE SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site 0002
Auckland, New Zealand
-
NZCR
Christchurch, 8011, New Zealand
-
Veritus Research Pty Ltd
Bayswater, Australia